A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019
Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Inhaled antibiotic treatment reduces the frequency of infective exacerbations in bronchiectasis: a single center, real life study Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006
Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice Source: Eur Respir J 2007; 30: Suppl. 51, 70s Year: 2007
Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019
The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016
Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Intrapulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=13 Year: 2004
Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017